MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Efficacy of Ramelteon on Speeding Up Sleep in Subjects With Delayed Sleep Phase Syndrome

Phase 2
Completed
Conditions
Sleep Disorders, Circadian Rhythm
Interventions
Drug: Placebo
Drug: Ramelteon
First Posted Date
2008-01-15
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
132
Registration Number
NCT00593736

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Azilsartan Medoxomil
Drug: Valsartan
First Posted Date
2008-01-11
Last Posted Date
2012-02-02
Lead Sponsor
Takeda
Target Recruit Count
984
Registration Number
NCT00591578

Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Azilsartan medoxomil and chlorthalidone
Drug: Chlorthalidone
First Posted Date
2008-01-11
Last Posted Date
2011-04-19
Lead Sponsor
Takeda
Target Recruit Count
551
Registration Number
NCT00591773

Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Azilsartan medoxomil
Drug: Placebo
First Posted Date
2008-01-11
Last Posted Date
2011-04-19
Lead Sponsor
Takeda
Target Recruit Count
413
Registration Number
NCT00591253

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Azilsartan Medoxomil and amlodipine
Drug: Amlodipine
First Posted Date
2008-01-11
Last Posted Date
2011-07-22
Lead Sponsor
Takeda
Target Recruit Count
566
Registration Number
NCT00591266

Safety of Ramelteon in Elderly Subjects

Phase 4
Completed
Conditions
Insomnia
Interventions
Drug: Ramelteon, zolpidem and placebo
First Posted Date
2007-12-06
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
33
Registration Number
NCT00568789

Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia

Phase 3
Terminated
Conditions
Hypercholesterolemia
Interventions
Drug: Lapaquistat acetate
Drug: Placebo
First Posted Date
2007-09-20
Last Posted Date
2012-05-24
Lead Sponsor
Takeda
Target Recruit Count
657
Registration Number
NCT00532558

Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia

Phase 3
Terminated
Conditions
Hypercholesterolemia
Interventions
Drug: Lapaquistat acetate and stable statin therapy
Drug: Stable statin therapy
First Posted Date
2007-09-20
Last Posted Date
2016-06-22
Lead Sponsor
Takeda
Target Recruit Count
411
Registration Number
NCT00532311

Safety Comparison of Pioglitazone and Glyburide in Type 2 Diabetes Subjects With Mild to Moderate Congestive Heart Failure

Phase 3
Terminated
Conditions
Diabetes Mellitus
Interventions
Drug: Pioglitazone
Drug: Glyburide
First Posted Date
2007-08-28
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
518
Registration Number
NCT00521820

Efficacy of Pioglitazone Compared to Glyburide in Treating Subjects With Type 2 Diabetes Mellitus and Mild Cardiac Disease

Phase 3
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Pioglitazone
Drug: Glyburide
First Posted Date
2007-08-28
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
300
Registration Number
NCT00521742
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy